Genprex (NASDAQ:GNPX) Sees Large Drop in Short Interest

Genprex (NASDAQ:GNPX) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 36,884 shares, a decrease of 95.8% from the July 15th total of 884,893 shares. Approximately 7.3% of the company’s stock are short sold. Based on an average daily trading volume, of 50,133 shares, the days-to-cover ratio is presently 0.7 days.

Genprex Stock Performance

Shares of NASDAQ GNPX traded up $0.29 during midday trading on Thursday, hitting $5.02. 86,598 shares of the company’s stock traded hands, compared to its average volume of 61,447. The firm has a fifty day moving average of $9.89 and a 200 day moving average of $25.81. Genprex has a 1 year low of $4.00 and a 1 year high of $1,210.00. The stock has a market capitalization of $2.51 million, a price-to-earnings ratio of -0.02 and a beta of -0.88.

Genprex (NASDAQ:GNPX) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($14.08) EPS for the quarter.

Analyst Ratings Changes

Several research firms have recently weighed in on GNPX. Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research note on Friday, July 17th. Wall Street Zen upgraded Genprex from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Genprex presently has an average rating of “Sell”.

Institutional Investors Weigh In On Genprex

A number of hedge funds have recently made changes to their positions in the company. Mayflower Financial Advisors LLC acquired a new position in shares of Genprex during the first quarter valued at about $36,000. Manchester Financial Inc. acquired a new stake in Genprex during the first quarter valued at $36,000. Finally, Susquehanna International Group LLP boosted its stake in shares of Genprex by 11.7% during the 3rd quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock worth $58,000 after acquiring an additional 35,661 shares in the last quarter. 14.05% of the stock is currently owned by hedge funds and other institutional investors.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.